Taiho Oncology, Inc. announced that the United States Food and Drug Administration (FDA) has accepted and granted priority review for the supplemental New Drug Application (sNDA) for LONSURF® Read More »

Pharmaceutical Care Management Association (PCMA) President and CEO JC Scott released the following statement on the Department of Health and Human Services’ proposal requiring drug companies to disclose the list price of prescription drugs in television ads Read More »

New safes for controlled substances will help combat opioid epidemic, reduce robbery incidents. All 228 CVS Pharmacy locations in Maryland area now using time-delay safe technology. Read More »

Researchers from the University of Central Florida recently received a $400,000 grant from the Juvenile Diabetes Research Foundation, which they will use to create a tube that resists infection and encapsulation and is inserted under the skin for the delivery of insulin via a pump. Read More »

A recent study published in European Endocrinology examined the effects of body lotions on capillary blood glucose measurement. Read More »

President Trump signed bipartisan legislation into law that will remove the barriers preventing pharmacists from helping patients find the least expensive way to purchase their prescription drugs. Read More »

The Pharmaceutical Care Management Association (PCMA) released the following statement on President Trump signing into law S. 2553/ S. 2554, the Know the Lowest Price Act of 2018 and the Patient Right to Know Drug Prices Act. Read More »

Health information technology (IT) should be the foundation of all business and clinical operations and not a secondary byproduct Read More »

Rite Aid Corporation (NYSE: RAD) released the following statement praising the U.S. Senate for passage of the Substance Use-Disorder Prevention that Promotes Opioid Recovery and Treatment (SUPPORT) for Patients and Communities Act (H.R. 6). Read More »

Tris ADHD Franchise Includes Quillivant XR ® (methylphenidate HCl), QuilliChew ER ® (methylphenidate HCl) and DYANAVEL® XR (amphetamine) Offering Multiple Treatment Options for Children and Adolescents with ADHD Read More »

Allergan issued the following announcement on Sept. 26.Allergan plc (NYSE: AGN), a leading global pharmaceutical company, today announced that the U.S. Read More »

Array BioPharma Inc. (NASDAQ: ARRY) today announced that the European Commission (EC) has approved BRAFTOVI® in combination with MEKTOVI® for the treatment of adult patients with unresectable or metastatic melanoma with a BRAFV600 mutation, as detected by a validated test. Read More »

Mylan's Dalfampridine Extended-Release Tablets, 10 mg, are indicated for patients with multiple sclerosis Read More »

Rite Aid Corporation (NYSE: RAD) announced that the company has established its Chemical Policy and expanded Restricted Substances List as part of ongoing efforts to continue meeting customer expectations for chemical management and product safety. Read More »

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) announced that the U.S. Food and Drug Administration (FDA) has accepted for review the supplemental Biologics License Application (sBLA) of EYLEA® (aflibercept) Injection for the treatment of diabetic retinopathy (DR), the leading cause of vision loss for patients with diabetes. Read More »

Triple-S Management Corporation (NYSE: GTS), announced that its managed care subsidiary, Triple-S Salud, Inc., on its behalf and on behalf of its Medicare Advantage subsidiary, Triple-S Advantage, Inc. ("Triple-S" or the "Company"), has entered into a three-year agreement with Abarca Health, LLC, a leading pharmacy benefits manager (PBM) in Puerto Rico, to consolidate the management of its prescription drug benefit programs for its Commercial and Medicare business lines. Read More »

The U.S. Food and Drug Administration is warning consumers and health care professionals about a voluntary recall of one lot of Montelukast Sodium Tablets – lot number MON17384, expiration 12/31/2019 – by Camber Pharmaceuticals, Inc., Piscataway, N.J. Read More »

Novartis announced today that the European Commission (EC) has approved Tafinlar® (dabrafenib) in combination with Mekinist® (trametinib) for the adjuvant treatment of stage III patients with BRAF V600 mutation-positive melanoma after complete surgical resection. Read More »

MYGRIN® 'Helping you turn the face of pain into a grin Read More »

The U.S. Food and Drug Administration today approved the first drug, Oxervate (cenegermin), for the treatment of neurotrophic keratitis, a rare disease affecting the cornea (the clear layer that covers the colored portion of the front of the eye). Read More »